Novel chemotherapeutic agents for gastrointestinal cancers

Current Opinion in Oncology

Volumn 11, Issue 4, 1999, Pages 299-304

  Royce, Melanie E ^a   Pazdur, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; RALTITREXED; UFT;

CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 0033062782     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199907000-00010     Document Type: Review

References (63)

1. 1 Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al.: Antitumor activity of 7-ethyl-10-[4-(1 -piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987, 47:5944-5947.
2. 2 Eckhardt SG: Irinotecan: a review of the initial phase I trials. Oncology 1998, 12(suppl 6):31-38.
3. 3 Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al.: A phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pre-treated with 5FU based chemotherapy. J Clin Oncol 1997, 15:251-260.
4. 4 Conti JA, Kemeny NE, Saaltz LB, Huang Y, Tong WP, Chou TC, et al.: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709-715.
5. 5 Pitot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. J Clin Oncol 1997, 15:2910-2919.
6. 6 Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, et al.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996, 14:1128-1135.
7. 7 Pitot HC: US pivotal studies of irinotecan in colorectal carcinoma. Oncology 1998, 12(Suppl 6):48-53. Summarizes the phase II trials reviewed by the US Food and Drug Administration that led to the conditional approval of irinotecan for the treatment of patients with advanced colorectal cancer.
8. 8 Cunningham D, Purhonen S, James RD, Punt CJ, Hickish TF, Heikkita R, et al.: Randomized trial of irinotecan plus supportive care versus supportive care atone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418. This study demonstrated that patients receiving irinotecan had prolonged survival, improved quality of life, and fewer disease-related symptoms compared with BSC alone.
9. 9 Rougier P, Van Cutsem E, Niederle N, Possinger K, Labianca R, Navarro M, et al.: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412. This article describes a prospective, nonblinded, multicenter, randomized phase III trial comparing irinotecan to infusional 5-FU as second-line chemotherapy for metastatic colorectal cancer. The results show a survival advantage associated with irinotecan with a comparable effect on quality of life and control of disease-related symptoms.
10. 10 Pazdur, R: Irinotecan: Toward clinical end points in drug development. Oncology 1998, 12(suppl 6):13-21.
11. 11 Enzinger PC, Ilson DH, Saltz LB, O'Reilly EM, Kelsen DP: Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology 1998, 12(suppl 6):110-113.
12. 12 Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, et al.: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997, 15:921-927.
13. 13 Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Puitenhuis M, et al.: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group Study. Ann Oncol 1995, 6:129-132.
14. 14 Buout JL, Mazard AM, Macquet JP: Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem Biophys Res Commun 1985, 133:347-353.
15. 15 Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998, 9:1053-1071.
16. 16 Becouarn Y, Ychou M, Ducreux M, Boral C, Bertheault-Cvitkovic F, Seitz JF, et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998, 16:2739-2744. This study demonstrated the safety and efficacy of oxaliplatin as monotherapy for patients with previously untreated metastatic colorectal carcinoma.
17. 17 Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, et al.: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998, 9:105-108.
18. 18 Machover D, Diaz Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95-98.
19. 19 Levi F, Dagliotti L, Perpoint B, Zidani R, Giacchetti S, Chollet P, et al.: A multicenter phase II trail of chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with previously untreated metastatic colorectal cancer [abstract 945]. Proc Am Soc Clin Oncol 1997, 16:266a.
20. 20 Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C, et al.: Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) [abstract 805]. Proc Am Soc Clin Oncol 1997, 16:229a.
21. 21 De Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al.: Oxaliplatin with high dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997, 33:214-219.
22. 22 Andre T, Louvet C, Raymond E, Tournigand C, de Gramont A: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998, 9:1251-1253. This study demonstrated that oxaliplatin produces further response when added to 5-FU even when patients have documented disease progression on the 5-FU regimen, indicating synergy between the two agents.
23. 23 Lokiec F, Wasserman E, Santoni J, Mahjoubi M, Misset JL, Cvitkovic E: Pharmacokinetics (PK) of the irinotecan/oxaliplatin (LOHP) combination: preliminary data of an ongoing phase I trial [abstract 771]. Proc Am Soc Clin Oncol 1997, 16:203a.
24. 24 Cvitkovic E, Wasserman E, Goldwasser F, Rougier P, Tigand JM, Mahjoubi M, et al.: Preliminary report on an oxaliplatin (LOHP) CPT-11 phase I trial in gastrointestinal (GI) malignancies: an active combination [abstract 806]. Proc Am soc Clin Oncol 1997, 16:229a.
25. 25 Aherne GW, Ward E, Lawrence N, Dobinson D, Clarke SJ, Musgrove H, et al.: Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamable quinazoline thymidylate synthase inhibitor, in preclinical models. Br J Cancer 1998, 77:221-226.
26. 26 Cunningham D, Zalcberg JR, Rath U, Oliver I, Van Cutsem E, Svensson C, et al. and the Tomudex Colorectal Cancer Study Group: Final results of a randomized trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996, 7:961-965.
27. 27 Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G, et al. on behalf of the Tomudex Colorectal Cancer Study Group: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998, 16:2943-2952.
28. 28 Pazdur R, Vincent M: Raltitrexed (Tomudex) vs 5-fluorouracil + leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized multicenter North American trial [abstract 801]. Proc Am Soc Clin Oncol 1997, 16:228a.
29. 29 Cunningham D: Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998, 77(suppl 2):15-21. This paper summarizes the three phase III clinical trials of raltitrexed in colorectal cancer patients.
30. 30 Blackledge G: New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br J Cancer 1998, 77(suppl 2):29-37.
31. 31 Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, et al.: 'Tomudex' (ZD1694): results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leukopenia. Eur J Cancer 1995, 31A:1945-1954.
32. 32 Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Adenis A, Seymour A: A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma, Ann Oncol 1997, 8:500-502.
33. 33 Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997, 15:389-400.
34. 34 Miller KD, Loehrer PJ, Picus J, Blanke C, John W, Clark J, et al.: A phase II trial of LY231514 in patients with unrosectable pancreatic cancer [abstract 1060]. Proc Am Soc Clin Oncol 1997, 16:297a.
35. 35 McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, et al.: A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998, 4:605-610.
36. 36 Calvert AH, Walling JM: Clinical studies with MTA. Br J Cancer 1998, 78(suppl3):35-40.
37. 37 Loh K, Stuart K, Cohn A, White C, Hines J, Miller W, et al.: A phase II trial of Thymitaq (AG337) in patients with adenocarcinoma of the pancreas [abstract 938]. Proc Am Soc Clin Oncol 1997, 16:265a.
38. 38 Rafi I, Boddy AV, Calvete JA, Taylor GA, Newell DR, Bailey NP, et al.: Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Oncol 1998, 16:1131-1141.
39. 39 Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, et al.: Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 1997, 3:911-921.
40. 40 Diab S, Britten C, Eckhardt G, Hammond L, Elledge R, Siu L, et al.: Phase I and pharmacokinetic (PK) study of the nonpolyglutamated thymidylate synthase (TS) inhibitor ZD9331 given as a 30 minute infusion every 3 weeks [abstract 869]. Proc Am Soc Clin Oncol 1998, 17:226a.
41. 41 The Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301-308. This study compares the efficacy of infusional versus bolus 5-FU using data from six randomized trials, and concludes that continuous infusion 5-FU gives superior tumor response with slight increase in overall survival compared with bolus 5-FU.
42. 42 Mani S, Kugler JW, Sciortino DF, Garcia JC, Ansari RH, Humerickhouse R, et al.: Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol 1998, 9:1035-1037.
43. 43 Akohoshi K, Chijiiwa Y, Hamada S, Hara K, Nakamura K, Nawata H, Matsui N: Complete response of early gastric cancer to uracil and tegafur. J Gastroenterol 1998, 33:864-867.
44. 44 Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D: Bioavailability and phase II study of oral UFT plus leucovorin inpatients with relapsed or refractory colorectal cancer. Cancer Chemother Pharmacol 1999, 43:221-226.
45. 45 Findly M, Van Cutsen E, Kocha W, Allman D, Laffranchi B, Griffin T, et al.: A randomized phase II study of Xeloda (capecitablne) in patients with advanced colorectal cancer [abstract 798]. Proc Am Soc Clin Oncol 1997, 16:227a
46. 46 Budman D, Meropol NJ, Reigner B, Creaven PJ, Stuart M, Lichtman SM, et al.: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998, 16:1795-1802.
47. 47 Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, et al.: A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998, 4:2755-2761.
48. 48 Mani S, Beck T, Chevlen E, Hochster H, O'Rourke M, Weaver C, et al.: A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC) [abstract 1083]. Proc Am Soc Clin Oncol 1998, 17:281a.
49. 49 Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, et al.: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998, 16:1450-1457.
50. 50 Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0,4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998, 34:1715-1720.
51. 51 Kurihara M, Koizumi W, Hasegawa K, Nakano L: Late phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer [abstract 1007]. Proc Am Soc Clin Oncol 1998, 17:262a.
52. 52 Baba H, Ihtsu A, Sakata Y, Mitachi Y, Sugimachi T, Taguchi T: Late phase II study of S-1 in patients with advanced colorectal cancer in Japan [abstract 1065]. Proc Am Soc Clin Oncol 1998, 17:277a.
53. 53 Mok TSK, Leung TWT, Chan ATC, Yeo W, Steinberg J, Hui P, Johnson PJ: A phase III randomized study of oral UFT (tegafur + uracil) as maintenance therapy in adjuvant treatment of surgically resected colorectal cancer patients [abstract 1042]. Proc Am Soc Clin Oncol 1998, 17:271a.
54. 54 Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990, 50:4417-4422.
55. 55 Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochannowski B, Tarassoff PG: Phase II trial of gemcitabine (2′,2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12:29-34.
56. 56 Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996, 73:101-105.
57. 57 Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
58. 58 Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, et al.: A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann Oncol 1996, 7:347-353.
59. 59 Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R. et al.: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999, 17:585-592. This study provides the maximum tol erated dose of gemcitabine when combined with protracted infusion 5-FU. It also demonstrated that the combination gemcitabine-5-FU is well tolerated and has promising antitumor activity in patients with pancreatic cancer.
60. 60 Christman K, Kelsen D, Saltz L, Tarassoff PG: Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994, 73:5-7.
61. 61 Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, et al.: Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of EORTC Early Clinical Trials Group. Ann Oncol 1994, 5:471-472.
62. 62 Fink U, Molle B, Daschner H, Errnisch S, Loffel J, Herrmann R: Phase II study of gemcitabine in metastatic colorectal cancer [abstract 507]. Proc Am Soc Clin Oncol 1992, 11:173a.
63. 63 Moore DF Jr, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL: Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 1992, 10:323-325.